Briacell Therapeutics Corp T.BCT

Alternate Symbol(s): BCTX | BCTXW

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.

TSX:BCT - Post by User

Briacell Therapeutics Corp

Bullboard Posts

Comment by Tradertimestwoon Jan 10, 2020 11:49pm

64 Views

Post# 30541447

RE:150M$ buyout

I'll take a 10x buyout....

Pugsrock2 wrote: With no dilution we are okay But there will likely be 3-4X increase in shares to raise dough for the endless arms of this study and then a 150M buyout will not cover my capital cost

Bullboard Posts

Full Circle Lithium goes global with its battery fire-fighter